Cancer and metabolic disease are usually discussed in separate rooms. In real life they share the same patients, the same kitchens and the same families. If you live with type 2 diabetes, insulin resistance or obesity, your cancer risk profile is different, and if you are in active cancer treatment, your glucose behaves differently too.
This guide covers three things: which cancers are hitting which communities hardest, what modern treatment actually looks like now, and which complementary approaches have real support behind them, including the ones that can actively interfere with treatment.
Nothing in this article is medical advice, and nothing here should be started, stopped or combined with treatment without your oncology team knowing. Several supplements widely marketed as "natural cancer support" measurably reduce the effectiveness of chemotherapy, radiation and immunotherapy.
Why metabolic health and cancer travel together
Three mechanisms link insulin resistance to cancer risk and outcomes:
Insulin and IGF-1 signalling. Chronically elevated insulin activates growth pathways (PI3K/AKT/mTOR) that many tumours use to proliferate. Higher circulating insulin also lowers IGF binding proteins, leaving more free IGF-1 available.
Chronic low-grade inflammation. Visceral adipose tissue releases inflammatory cytokines that create an environment favourable to tumour development and progression.
Hormonal conversion in fat tissue. Adipose tissue converts androgens to estrogens, which is part of why obesity raises risk of postmenopausal breast and endometrial cancers.
The International Agency for Research on Cancer has linked excess body fat to at least 13 cancer types, including colorectal, postmenopausal breast, endometrial, kidney, liver, pancreatic, gallbladder, oesophageal, gastric, ovarian, thyroid, multiple myeloma and meningioma.
Type 2 diabetes itself carries an independent association with liver, pancreatic, endometrial, colorectal, breast and bladder cancer risk in large pooled analyses. Association is not proof of causation, shared risk factors explain part of it, but the overlap is consistent enough that oncology and endocrinology increasingly plan together.
Where the burden falls unevenly
Cancer does not distribute itself evenly, and the reasons are far more about access, exposure, screening and infection rates than about genetics alone.
Black communities. Prostate cancer incidence is roughly 70% higher in Black men than white men in the US, with mortality around twice as high, and onset often earlier. Black women are diagnosed with triple-negative breast cancer at roughly twice the rate of white women and face about a 40% higher breast cancer death rate despite similar overall incidence. Colorectal cancer incidence and mortality also run higher. Multiple myeloma occurs at roughly double the rate.
Latino and Hispanic communities. Liver, stomach and gallbladder cancers occur at elevated rates, driven substantially by H. pylori infection, hepatitis and metabolic liver disease. Cervical cancer incidence is roughly 30% higher than in white women, largely a screening-access story. Childhood leukaemia rates are also elevated.
East and Southeast Asian communities. Liver cancer risk is markedly elevated, closely tied to chronic hepatitis B, often acquired at birth and frequently undiagnosed. Stomach cancer rates are among the highest of any US group, again tied to H. pylori. Nasopharyngeal cancer is notably higher in people of Southern Chinese descent. Lung cancer in never-smoking Asian women is a distinct and under-recognised pattern.
South Asian communities. Oral and oropharyngeal cancers are elevated where betel quid, paan and gutka use is common. Gallbladder cancer rates are high in populations from northern India. Breast cancer often presents at younger ages than in white populations.
Indigenous and Native communities. Liver, kidney, stomach, colorectal and cervical cancers all occur at elevated rates, alongside the highest diabetes prevalence of any US group, the two burdens compound each other.
Everyone. Early-onset colorectal cancer, diagnosis before 50, has been rising steadily for two decades across all groups. Screening now begins at 45 for average risk, and earlier with family history or symptoms.
Three of the highest-burden cancers in these lists, liver, stomach and cervical, are substantially preventable through hepatitis B vaccination and treatment, H. pylori testing and eradication, and HPV vaccination plus cervical screening. Ask your provider about all three.
What modern treatment actually looks like
Survival has improved meaningfully, and the reasons are specific.
Immunotherapy. Checkpoint inhibitors release the brakes on your own T-cells. They have changed the outlook in advanced melanoma, several lung cancers, kidney cancer, bladder cancer and mismatch-repair-deficient tumours. They do not work for everyone, and they carry their own autoimmune side effects, including immune-mediated diabetes, which is rare but real and requires urgent attention if it occurs.
Targeted therapy. Drugs matched to a specific mutation found by genomic testing of the tumour, EGFR, ALK, BRAF, HER2, KRAS G12C, BRCA and others. If your tumour has not been sequenced, ask why.
CAR-T and cellular therapy. Your own T-cells re-engineered to recognise the cancer. Now standard in several blood cancers after other lines fail, with solid-tumour trials expanding.
Antibody-drug conjugates. Chemotherapy chemically attached to an antibody that delivers it directly to tumour cells, sparing more healthy tissue. A major driver of recent breast, bladder and lung cancer gains.
Precision radiation. Stereotactic body radiotherapy and proton therapy deliver higher doses to a tighter volume with fewer sessions and less collateral damage.
Robotic and minimally invasive surgery. Shorter recovery, less blood loss, better preservation of function, particularly relevant in prostate and colorectal surgery.
Earlier detection. Multi-cancer early detection blood tests, low-dose CT for lung cancer in eligible smokers, and better cervical and colorectal screening pathways including stool-DNA and self-collected HPV testing.
The uncomfortable truth is that access to all of the above varies enormously by insurance status, geography and which hospital you land in. Being treated at, or getting a second opinion from, a comprehensive cancer centre changes what is offered.
Complementary support that has real evidence
"Complementary" means alongside treatment. It never means instead of treatment, and every item below belongs in a conversation with your oncology team before you start it.
Exercise. The strongest evidence of anything in this section. Supervised aerobic and resistance training during and after treatment reduces cancer-related fatigue, preserves muscle, improves quality of life, and in colorectal and breast cancer cohorts is associated with better outcomes. Guidelines now recommend roughly 150 minutes of moderate activity plus two resistance sessions weekly, adapted to what you can do that week.
Protein and weight maintenance. Losing muscle during treatment (sarcopenia) predicts worse tolerance of chemotherapy and worse outcomes. Many patients need substantially more protein than usual, often in the range of 1.0–1.5 g per kg of body weight per day. An oncology dietitian is a genuine intervention, not a luxury.
Whole-food dietary patterns. Mediterranean-style and plant-forward patterns have the best supportive data for survivorship, cardiovascular protection and glycaemic control. No specific food cures cancer, and no evidence supports "starving" tumours through extreme carbohydrate restriction outside of trials.
Ginger for nausea. Reasonable trial evidence for reducing chemotherapy-induced nausea when used as an adjunct to standard antiemetics.
Acupuncture. Supported by oncology society guidelines for chemotherapy-induced nausea, aromatase-inhibitor joint pain and some treatment-related fatigue.
Vitamin D. Correct a documented deficiency; deficiency is common and worth testing. High-dose supplementation without deficiency has not shown cancer benefit.
Sleep and stress interventions. Cognitive behavioural therapy for insomnia, mindfulness-based stress reduction and yoga have consistent trial support for fatigue, anxiety, sleep and quality of life during treatment.
Scalp cooling, mouth care, exercise for neuropathy. Practical, evidence-supported measures that make treatment more tolerable, ask specifically about them.
Curcumin, medicinal mushrooms, green tea, mistletoe, high-dose vitamin C. Frequently discussed, biologically interesting, and currently supported by early or mixed evidence only. Several carry interaction risks (below). Interest is not the same as proof.
What can actively interfere
This section matters more than the last one. These are documented pharmacological interactions, not hypotheticals.
St. John's wort. Induces CYP3A4 and can dramatically lower blood levels of many chemotherapy and targeted agents, including imatinib, irinotecan and docetaxel. Considered contraindicated in most active cancer treatment.
High-dose antioxidants during radiation or certain chemotherapies. Vitamins C and E, N-acetylcysteine and similar at supplement doses may in theory protect tumour cells from the oxidative damage that treatment relies on. Food-level intake is not the concern; high-dose supplements are.
Grapefruit and Seville orange. Inhibit CYP3A4 and can raise drug levels into toxic territory for many oral oncology drugs.
Green tea extract (concentrated EGCG). Reported to interfere with bortezomib, and high-dose extracts carry liver toxicity reports. Drinking green tea is a different matter from swallowing concentrated capsules.
Turmeric/curcumin at supplement doses. Affects drug metabolism and platelet function; caution around surgery and with anticoagulants.
High-dose vitamin E, fish oil, garlic, ginkgo, ginger at high doses. All can increase bleeding risk, which matters around surgery, biopsies and low platelet counts.
Estrogenic botanicals, soy isoflavone concentrates, black cohosh, dong quai, red clover, need individual discussion in hormone-receptor-positive breast cancer. Whole soy foods are generally considered safe and are viewed favourably in survivorship data; concentrated extracts are a separate question.
Anything hepatotoxic, kava, comfrey, high-dose niacin, some Ayurvedic and traditional preparations, when your liver is already processing chemotherapy.
Steroids and your glucose. Dexamethasone and prednisone are routine parts of many chemotherapy protocols and will raise blood glucose, sometimes dramatically, for days after each cycle. If you have diabetes, plan for this in advance with your diabetes team rather than reacting to it. Continuous glucose monitoring during treatment cycles is genuinely useful here.
Screening: the part you control today
- Colorectal: begin at 45 for average risk; earlier with family history, IBD or symptoms. Colonoscopy, or stool-based testing done consistently.
- Breast: mammography discussion from 40; earlier and with MRI where family history, genetics or dense tissue warrant it.
- Cervical: HPV-based screening from 25–30; self-collection now available in many settings.
- Prostate: PSA discussion from 45 for average risk, and from 40 for Black men or anyone with a family history.
- Lung: annual low-dose CT from 50 with a 20 pack-year history, current or quit within 15 years.
- Liver: ultrasound surveillance if you have hepatitis B or C, cirrhosis or advanced metabolic liver disease, the group that includes many people with long-standing type 2 diabetes.
- Stomach: H. pylori testing and eradication if you are from a high-incidence population or have a family history.
- Skin, oral, thyroid: clinical examination as part of routine care, and lower your threshold to raise anything that has changed.
Questions worth taking to your appointment
- Has my tumour had genomic or biomarker testing, and what did it show?
- Am I eligible for immunotherapy, a targeted agent or a clinical trial?
- Would a second opinion at a comprehensive cancer centre change my options?
- Which of my current supplements should I stop, and when?
- Will my treatment include steroids, and how should I adjust my diabetes plan around them?
- Can I be referred to an oncology dietitian and an exercise oncology programme?
- What symptoms mean I should call you rather than wait for the next visit?
Where GLUCORAiQ fits
We are not a cancer app and will never pretend to be. What we can do during treatment is keep the metabolic side legible: log meals when appetite is unpredictable, watch what steroid cycles do to your glucose, track weight and protein so muscle loss gets caught early, log symptoms and questions between appointments, and export a clean report your oncology and diabetes teams can both read.
Frequently asked questions
Can natural remedies treat cancer on their own?
No. Studies of patients who chose alternative therapy instead of conventional treatment for curable cancers have consistently found substantially higher death rates. Complementary approaches support you through treatment; they do not replace it.
Does sugar feed cancer?
All cells use glucose, and tumours are metabolically active, but cutting sugar does not starve a tumour, and severe restriction during treatment often causes harmful weight and muscle loss. What does matter is long-term metabolic health: chronically high insulin is associated with higher risk. Eat a whole-food pattern, keep protein up, and treat this as a long game rather than a treatment tactic.
I take turmeric, fish oil and a multivitamin. Do I need to stop?
Bring the actual bottles to your next appointment and let your oncology pharmacist decide. Some are fine, some need pausing around infusions or surgery, and a few need stopping entirely. Do not guess, and do not simply stop telling them.
Why is my blood sugar suddenly out of control during chemotherapy?
Most likely the steroids given alongside it. Dexamethasone can raise glucose substantially for two to four days after each dose. This is expected, temporary and manageable, but it needs a plan from your diabetes team, not silent tolerance.
My family says cancer runs in us. What should I actually do?
Ask for a genetic counselling referral. Certain patterns, breast or ovarian cancer under 50, multiple relatives with the same cancer, male breast cancer, colorectal cancer under 50, Ashkenazi Jewish ancestry, meet criteria for testing that changes your screening schedule and sometimes your relatives'.
Is a second opinion insulting to my doctor?
No. It is normal, expected, and most oncologists actively encourage it. In cancer care the treatment plan is the product, and a second read of that plan is a reasonable thing to want.
This article is educational and is not medical advice, diagnosis or treatment. Cancer care decisions belong with your oncology team. Tell them about every supplement, herb and over-the-counter product you use, including ones you consider harmless.